Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

18.5K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Antibody Actions01:26

Antibody Actions

3.9K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
3.9K
Antibody Structure and Classes01:25

Antibody Structure and Classes

10.3K
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
10.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vohwinkel syndrome: Clinical and genetic insights from 26 years of follow-up.

JAAD case reports·2026
Same author

Cutaneous eruptions associated with human polyomavirus 6 and human polyomavirus 7 in liver transplant recipients: Two case reports.

JAAD case reports·2026
Same author

IL4Rα blockade inhibits proliferation of malignant lymphocytes and the immunosuppressive tumor microenvironment of mycosis fungoides.

Journal for immunotherapy of cancer·2026
Same author

CTCL During Immunomodulatory Treatment: Diagnostic Gaps and the Importance of Distinguishing Unmasking From True Onset: Comment on "Mycosis Fungoides Following IL-17 Inhibitor Treatment: A Case Series of Five Patients".

The Journal of dermatology·2026
Same author

Serum proteomic and single-cell transcriptomic profiling reveals immunoproteomic features distinguishing early-stage mycosis fungoides from atopic dermatitis.

The Journal of investigative dermatology·2026
Same author

Skin health in oncology: evidence-based skin care for cancer patients.

The oncologist·2026
Same journal

The Evidence Is In: Devices and Biologics Reshaping Modern Dermatology.

Dermatologic clinics·2026
Same journal

Energy-Based Devices for Body Contouring.

Dermatologic clinics·2026
Same journal

Microfocused Ultrasound with Visualization for Skin Tightening: Clinical Applications, Safety, and Technical Considerations.

Dermatologic clinics·2026
Same journal

Devices in Onychomycosis: A Status Update.

Dermatologic clinics·2026
Same journal

Acne Laser Devices in Dermatology.

Dermatologic clinics·2026
Same journal

Fractional Laser Therapy for Androgenetic Alopecia: Mechanisms, Clinical Evidence, and Practical Implementation.

Dermatologic clinics·2026
See all related articles

Related Experiment Video

Updated: Apr 1, 2026

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.8K

Monoclonal Antibodies.

Larisa J Geskin1

  • 1Comprehensive Cutaneous Oncology Center, Department of Dermatology, Columbia University, 161 Fort Washington Avenue, 12th floor, New York, NY 10032, USA.

Dermatologic Clinics
|October 5, 2015
PubMed
Summary
This summary is machine-generated.

Monoclonal antibodies (mAbs) have transformed cancer treatment, showing high efficacy and safety in cutaneous lymphomas. These targeted therapies offer promising sequential treatment options for patients.

Keywords:
Antibody conjugatesAntibody therapyClinical trialsCutaneous lymphoma

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K
Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

44.1K

Related Experiment Videos

Last Updated: Apr 1, 2026

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.8K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K
Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

44.1K

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • Monoclonal antibodies (mAbs) represent a significant advancement in cancer therapy.
  • Targeted approaches against malignant cells and the tumor microenvironment are effective in hematologic malignancies, including cutaneous lymphomas.

Purpose of the Study:

  • To review the role and efficacy of mAb-based therapy in cutaneous T-cell lymphoma (CTCL).
  • To highlight the success of mAbs in clinical trials for CTCL, noting high response rates and a favorable toxicity profile.

Main Methods:

  • Review of clinical trial data and approved therapies involving monoclonal antibodies for CTCL.
  • Analysis of the therapeutic potential and safety profile of existing and emerging mAb treatments.

Main Results:

  • mAb-based therapy for CTCL has demonstrated high response rates in clinical trials.
  • These therapies exhibit a favorable toxicity profile, making them well-tolerated.
  • Several mAbs and antibody-based conjugates are approved, with numerous others in development.

Conclusions:

  • Monoclonal antibodies are a cornerstone of modern cancer therapy, particularly for CTCL.
  • Their efficacy, safety, and potential for sequential administration position them as valuable tools in managing cutaneous lymphomas.